alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topic

Drug trials: efficacy and safety

902 studies in this group. A computer grouped them by what their titles and summaries are about, not by a hand-made list. The name describes most of the group, not every study in it.

Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.

Highest usefulness score first. Studies without a score come last.

  1. Natural products and derivatives affecting neurotransmission relevant to Alzheimer's and Parkinson's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Neuro-Signals 2005-01-01 End-of-life care

    The two major neurodegenerative diseases Alzheimer's disease (AD) and Parkinson's disease (PD) are characterised by low levels in the brain of the neurotransmitters acetylcholine (ACh) and dopamine (DA), respectively.

  2. Acetylcholinesterase inhibitors: novel activities of old molecules

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Pharmacological research 2004-10-01 Treatments

    The therapeutic approach for improving the cognitive function in patients with Alzheimer's disease (AD) is mainly based on the potentiation of central cholinergic activity and is achieved clinically by the use of acetylcholinesterase (AChE) inhibitors such as tacrine, donepezil, rivastigmine, galantamine and other drugs currently in clinical trials.

  3. Emerging Therapies for Vascular Dementia and Vascular Cognitive Impairment

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Stroke 2004-03-09 Treatments

    From a public health viewpoint, recognition of VCI before the development of dementia and correction of vascular burden on the brain may lead to a global decrease of incident dementia.

  4. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Drugs & aging 2004-01-01 Treatments

    There is also a significant correlation between acetylcholinesterase inhibition and observed cognitive improvement.

  5. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. International journal of geriatric psychiatry 2003-09-01 Treatments

    There is increasing evidence for the involvement of glutamate-mediated neurotoxicity in the pathogenesis of Alzheimer's disease (AD).

  6. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Sleep medicine 2003-07-01 Brain scans and imaging

    Fourteen patients were commenced on melatonin over the specified time period (13 male, median RBD onset age 56 years, range 20-77 years).

  7. Cholinesterase inhibitors for the treatment of Alzheimer's disease:: getting on and staying on

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Current therapeutic research, clinical and experimental 2003-04-01 Treatments

    ChE inhibitors provide symptomatic benefit in AD across key symptom domains.

  8. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. The Journal of pharmacology and experimental therapeutics 2003-03-20 Treatments

    Galantamine (Reminyl), an approved treatment for Alzheimer's disease (AD), is a potent allosteric potentiating ligand (APL) of human alpha 3 beta 4, alpha 4 beta 2, and alpha 6 beta 4 nicotinic receptors (nAChRs), and of the chicken/mouse chimeric alpha 7/5-hydroxytryptamine3 receptor, as was shown by whole-cell patch-clamp studies of human embryonic kidney-293 cells stably expressing a single nAChR subtype.

  9. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. CNS drug reviews 2003-01-01 Treatments

    Memantine has been demonstrated to be safe and effective in the symptomatic treatment of Alzheimer's disease (AD).

  10. Acetylcholinesterase inhibitory activity of some Amaryllidaceae alkaloids and Narcissus extracts

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Life sciences 2002-10-01 Treatments

    Amaryllidaceous plants produce pharmacologically active alkaloids, galanthamine being the most interesting for its use in the treatment of Alzheimer's disease as a cholinesterase inhibitor.

  11. Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Biochemistry 2002-03-01 Treatments

    Rivastigmine, a carbamate inhibitor of acetylcholinesterase, is already in use for treatment of Alzheimer's disease under the trade name of Exelon.

  12. Comparison of Citalopram, Perphenazine, and Placebo for the Acute Treatment of Psychosis and Behavioral Disturbances in Hospitalized, Demented Patients

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. American Journal of Psychiatry 2002-03-01 Clinical safety

    Patients treated with citalopram or perphenazine showed statistically significant improvement on several Neurobehavioral Rating Scale factor scores.

  13. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. International psychogeriatrics 2002-01-01 Treatments

    Acetylcholinesterase (AChE) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain acetylcholine (ACh) levels.

  14. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Clinical pharmacokinetics 2002-01-01 Treatments

    A conceptual model for cholinesterase inhibitors has been proposed, linking enzyme inhibition, clinical efficacy and adverse effects.

  15. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. European neurology 2002-01-01 Treatments

    Cholinesterase inhibitors have produced the best evidence of clinical efficacy for treating patients with Alzheimer's disease (AD).

  16. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Biological psychiatry 2001-02-01 Treatments

    Cholinesterase inhibitors are the only approved drug treatment for patients with mild to moderately severe Alzheimer's disease.

  17. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Current medical research and opinion 2001-01-01 Treatments

    Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the elderly, characterised by widespread loss of central cholinergic function.

  18. Sleep disturbances in patients with Alzheimer's disease: epidemiology, pathophysiology and treatment

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. CNS drugs 2001-01-01 Health systems and care delivery

    Older adults represent an ever-growing proportion of the population of the industrialised nations, with a corresponding increase in the numbers of patients with dementing disorders.

  19. Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Current medicinal chemistry 2000-03-01 Treatments

    A wide range of evidence shows that acetylcholinesterase (AChE) inhibitors can interfere with the progression of Alzheimer's disease (AD).

  20. The cholinergic hypothesis of Alzheimer's disease: a review of progress

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of neurology, neurosurgery, and psychiatry 1999-02-01 Treatments

    Alzheimer's disease is one of the most common causes of mental deterioration in elderly people, accounting for around 50%-60% of the overall cases of dementia among persons over 65 years of age.

  21. Alpha-1 noradrenergic receptor stimulation impairs prefrontal cortical cognitive function

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Biological psychiatry 1999-01-01 Drug development

    These findings demonstrate that alpha-1 adrenoceptor stimulation in the PFC impairs cognitive function.

  22. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Drug safety 1998-12-01 Treatments

    Tacrine is associated with hepatotoxicity while other cholinesterase inhibitors seem devoid this adverse effect.

  23. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Clinical therapeutics 1998-07-01 Treatments

    Rivastigmine (ENA 713, or carbamoylatine) is an acetylcholinesterase (AChE) inhibitor with brain-region selectivity and a long duration of action.

  24. Anticholinesterases: medical applications of neurochemical principles

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of neurochemistry 1995-05-01 Risk factors

    Cholinesterases form a family of serine esterases that arise in animals from at least two distinct genes.

  25. Alzheimer disease, attention, and the cholinergic system

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Alzheimer disease and associated disorders 1995-01-01 Cognitive tests and assessment

    Recent neuropsychological studies suggest that, in addition to prominent mnemonic dysfunction, attentional impairments are a core feature of Alzheimer disease (AD).

From across this topic

10 of the 902 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.

Other topics